Stablecoin Development 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7NovExpected
Q3 2025
-0.99
-0.97
-0.94
-0.91
Expected EPS
-0.9077355
Actual EPS
-0.9941865

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B9P1.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ocular Therapeutix
OCUL
Mkt Cap1.85B
Ocular Therapeutix focuses on developing treatments for eye diseases, directly competing with Novabay's eye care products.
National Vision
EYE
Mkt Cap1.97B
National Vision Holdings operates in the eye care market, offering products that can be seen as alternatives to Novabay's offerings.
Alcon
ALC
Mkt Cap37.27B
Alcon specializes in eye care products, including surgical, vision care, and ophthalmic pharmaceuticals, competing across several of Novabay's key areas.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its Vision Care division, competes in the eye health sector, offering products that rival Novabay's.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad range of healthcare products, including treatments for eye conditions that compete with Novabay's pharmaceuticals.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a wide range of healthcare products, including ophthalmic solutions that compete with Novabay's eye care products.
Bausch Health Companies
BHC
Mkt Cap1.99B
Bausch Health Companies, through its eye health division, directly competes with Novabay in the ophthalmology and optometry markets.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is involved in developing treatments for eye diseases, offering products that compete with Novabay's portfolio.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie, having acquired Allergan, competes in the eye care sector with a portfolio that includes treatments for various eye conditions, challenging Novabay's market share.

About

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Show more...
CEO
Mr. Michael Kazley
Employees
13
Country
United States
ISIN
US66987P5089

Listings

0 Comments

Share your thoughts

FAQ

What is Stablecoin Development stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Stablecoin Development stocks are traded under the ticker B9P1.MU.
What were Stablecoin Development earnings last quarter?
B9P1.MU earnings for the last quarter are -0.99 EUR per share, whereas the estimation was -0.91 EUR resulting in a -9.52% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Stablecoin Development have?
As of April 12, 2026, the company has 13 employees.
In which sector is Stablecoin Development located?
Stablecoin Development operates in the Health & Wellness sector.
When did Stablecoin Development complete a stock split?
Stablecoin Development has not had any recent stock splits.
Where is Stablecoin Development headquartered?
Stablecoin Development is headquartered in Emeryville, United States.